OncoSil Medical Ltd Issues 1,048 Shares via Option Conversion on ASX

Details of OncoSil Medical’s Option Exercises and Share Capital Growth

On 23 July 2026, OncoSil Medical Ltd completed the exercise of convertible securities resulting in the issuance and ASX quotation of 1,048 new ordinary shares. This involved two option conversions on the same day: 774 options from the OSLOD class expiring 31 July 2027 exercised at AUD $1.20 per share, and 274 options from the OSLOE class expiring 30 June 2027 exercised at AUD $0.90 per share. The company promptly applied for quotation of these shares on the same date.

The newly issued shares rank equally with existing ordinary shares, carrying identical voting rights, dividend entitlements, and economic benefits. This transaction reflects a standard capital management practice among ASX-listed companies, converting convertible securities into equity. The simultaneous exercise indicates active management of OncoSil’s equity incentive framework and investor or employee participation in its capital structure.

OncoSil Medical’s Share Capital Post-Issuance

Following this issuance, OncoSil Medical’s total ordinary shares on issue now stand at 30,890,478. The company continues to hold a significant number of outstanding options and performance rights across various classes with differing expiry dates and exercise prices, representing potential future dilution if exercised.

OncoSil’s quoted securities on ASX include ordinary fully paid shares and four classes of quoted options: 12,081,320 options expiring 30 June 2027 (OSLOE); 2,140,009 options expiring 20 December 2027 (OSLOC); 7,661,625 options expiring 31 July 2027 (OSLOD); and 4,253,161 options expiring 30 April 2027 (OSLO). Additionally, the company holds unquoted performance rights totaling 228,750 shares and various unquoted option series with exercise prices ranging from nil to AUD $48.00 and expiry dates extending to 2030. This layered capital structure is typical in biomedical and medical device sectors, where equity incentives are crucial for talent retention.

Complexity of OncoSil Medical’s Options and Performance Rights Structure

OncoSil Medical’s register reveals a sophisticated equity management strategy, with multiple option and performance rights series serving different roles within its incentive and capital structure. The quoted options are publicly traded on the ASX, reflecting market confidence in their potential exercise. The largest quoted option series is OSLOE, with over 12 million options expiring 30 June 2027, followed by OSLOD with approximately 7.66 million options expiring 31 July 2027, both representing significant potential dilution.

Unquoted securities, including performance rights totaling 252,906 shares, are likely linked to employee incentive schemes and milestone-based awards. The presence of options with exercise prices as high as AUD $48.00 (OSLAN, expiring 25 October 2027) indicates issuance during periods of higher share valuations, reflecting historical trading performance or strategic capital-raising events.

Mechanics and Timing of the 23 July 2026 Option Exercises

Both option series were exercised simultaneously on 23 July 2026, coinciding with OncoSil’s application for quotation of the resulting shares. This timing aligns with common ASX practices to ensure new shares become tradeable promptly. The company has not disclosed whether all outstanding options in the OSLOD or OSLOE series were exercised, so additional options may remain unexercised.

The exercise prices reflect different valuation points: OSLOD options at AUD $1.20 and OSLOE options at AUD $0.90, suggesting OSLOE options were granted earlier when valuations were lower. Exercising both series on the same day may indicate portfolio management decisions by option holders in response to market conditions.

OncoSil Medical’s Role in the Medical Device Sector

As a biomedical and medical device company, OncoSil Medical’s complex capital structure is typical of health technology firms that use equity incentives to attract and retain scientific, engineering, and clinical talent. The sector’s long development cycles, regulatory hurdles, and capital intensity justify such equity frameworks aligned with long-term stakeholder interests.

OncoSil’s capital management, including multiple option and performance right series, demonstrates best practices for retaining specialized personnel in a competitive biomedical market. The use of performance rights alongside standard options suggests conditional equity awards tied to milestones, ensuring focus on strategic objectives.

Recent Capital Activity and Shareholder Engagement

The exercise of 1,048 shares through option conversions reflects active optionholder participation. Though modest relative to total shares, these exercises generate cash proceeds without external capital raises. Specifically, OSLOD options exercised at AUD $1.20 raised AUD $928.80, and OSLOE options at AUD $0.90 raised AUD $246.60. These represent genuine capital contributions.

Simultaneous exercise suggests optionholders responded to favorable market or company-specific catalysts around 23 July 2026. The company did not disclose whether all options were exercised, indicating further potential dilution exists.

Monitoring Outstanding Options and Performance Rights

OncoSil Medical’s outstanding options pose significant dilution risk. The four quoted option classes total approximately 26.14 million securities, with unquoted options and performance rights adding about 1.34 million potential shares. Full exercise or vesting could substantially increase the share count. Investors should closely monitor exercise trends, especially in the OSLOE and OSLOD series, which represent around 76% of quoted options and will heavily influence future share count.

Unquoted performance rights, such as the OSLAM series expiring 25 October 2026 with 24,156 rights, are particularly important due to their contingent nature. These may vest or expire depending on performance conditions. Other unquoted options with varied exercise prices and expiry dates likely stem from historical incentive plans and pose less immediate dilution risk than near-term quoted options.

Comparison of OncoSil Medical’s Capital Structure with ASX Biomedical Peers

OncoSil’s multiple option series with diverse strike prices and expiries reflect common practices among ASX-listed biomedical and medical device companies competing globally for talent and capital. Options expiring in 2027, 2028, and 2030 indicate rolling equity incentive programs for ongoing retention. Strike prices ranging from nil to AUD $48.00 reveal historical valuation fluctuations, with higher-priced options issued during optimistic periods.

Exercises at relatively low strike prices (AUD $0.90 to AUD $1.20) compared to the highest strike price options suggest significant share price volatility or declines from past highs, typical in the biomedical sector where clinical and regulatory developments impact valuations. This capital structure illustrates both the company’s success in talent attraction and the cyclical nature of investor sentiment.

Risk Factors for Shareholders and Option Holders

Shareholders face notable dilution risk from outstanding options and performance rights. If all 26.14 million quoted options are exercised, the current 30.89 million shares could increase by up to 85%, significantly diluting existing ownership. The OSLOE and OSLOD series, totaling about 20 million options, pose the greatest dilution threat.

Operational and regulatory risks inherent to the medical device sector may affect OncoSil’s ability to meet equity obligations or justify option valuations. Clinical trial failures, regulatory setbacks, competition, or partnership issues could depress share prices, rendering options worthless or prompting restructuring. Investors and option holders should monitor clinical progress, regulatory milestones, and market dynamics closely, as adverse developments could materially impact both ordinary shares and outstanding options.